Develop innovative therapies to treat patients with rare or otherwise debilitating disease
Active 2018–2026. The register lists this client once for every firm that files on its behalf; all 3 of its records are shown together here.
These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.
| Year | Firm | Period | Amount | Doc |
|---|---|---|---|---|
| 2022 | KNIGHT CAPITOL CONSULTANTS |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$60,000 | |
| 2022 | REGENXBIO |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$70,000 | |
| 2022 | KNIGHT CAPITOL CONSULTANTS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$60,000 | |
| 2022 | REGENXBIO |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$70,000 | |
| 2022 | KNIGHT CAPITOL CONSULTANTS |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$60,000 | |
| 2022 | REGENXBIO |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$82,000 | |
| 2022 | KNIGHT CAPITOL CONSULTANTS |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$60,000 | |
| 2022 | REGENXBIO |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$150,000 |
| Firm | Filings | Amount |
|---|---|---|
| REGENXBIO IN-HOUSE | 24 | $1,740,000 |
| KNIGHT CAPITOL CONSULTANTS | 13 | $665,000 |
| THEGROUP DC, LLC | 4 | $180,000 |
| Issue | Activities |
|---|---|
| Health Issues | 37 |
| Copyright/Patent/Trademark | 22 |
| Trade (domestic/foreign) | 21 |
| Taxation/Internal Revenue Code | 19 |
| Immigration | 19 |
| Medicare/Medicaid | 12 |
| Pharmacy | 11 |